• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Covis acquires global rights to Eklira and Duaklir

Covis Pharma will pay AstraZeneca $270 million for global rights to the Eklira (Turdorza, Bretaris) aclidinium bromide and Duaklir (Brimica) aclidinium bromide/formoterol DPIs, the companies have announced. Both DPIs are marketed for the treatment of COPD. In addition to the $270 million payment, Covis said that it “will also cover certain ongoing development costs” for the dry powder inhalers. Covis previously acquired global rights to Alvesco MDI along with Omnaris and Zetonna nasal sprays from AstraZeneca in 2018.

Eklira/Bretaris Genuair was approved in Europe in July 2012, just after Tudorza was approved by the FDA. Duaklir was approved in Europe in November 2014 and in the US in March 2019. AstraZeneca acquired most of the rights to the two inhalers when it acquired Almirall’s respiratory portfolio in 2014. In February 2015, AstraZeneca also acquired the US and Canadian rights to the aclidinium DPIs from Actavis. Circassia acquired US rights to Turdorza and Duaklir from AstraZeneca in 2017.

Covis CEO Michael Porter said, “This acquisition represents a highly strategic and synergistic transaction with AstraZeneca, enabling Covis to offer a full continuum of best-in-class therapies for allergic rhinitis, asthma and COPD. As a result of the acquisition, Covis is firmly placed as one of the top 10 respiratory companies in the world. Combined with our presence in other therapeutic areas and our internal life cycle management and product development programs, this transaction will further enhance our efforts to meet the evolving needs of patients and their health care providers.”

Read the Covis Pharma press release.
Read the AstraZeneca press release.

Share

published on November 2, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews